益生菌Escherichia coli Nissle1917功能研究进展

大肠埃希菌Nissle1917，简称EcN，是益生菌中为数不多的革兰氏阴性菌，在临床上主要用于克罗恩病、溃疡性结肠炎等胃肠功能障碍。其机制在于EcN能在人体肠道定殖，并阻止病原菌对肠道黏膜的侵袭，对肠道黏膜屏障具有保护和修护作用。EcN还参与机体的免疫调控，平衡免疫因子的分泌，增强宿主免疫能力，进而缓解和治疗炎症。最进研究发现，EcN具有肿瘤靶向作用，是良好的药物载体，且与化疗药物联用可增强药物抗肿瘤的疗效，为抗肿瘤治疗提供了新的思路。

Advances in functional studies of probiotic Escherichia coli Nissle1917

Escherichia coli Nissle1917 (EcN), as a probiotic, is mainly used to treat a variety of gastrointestinal disorder including inflammatory bowel disease, chronic constipation. EcN prevents human intestinal epithelial cells from adherent and invasion of evasive pathogen, and protects intestinal mucosal barrier and inhabits pathological inflammation. EcN also enhances intestinal immune function and regulates cytokine secretion. Recently, EcN has shown anti-cancer efficacy via tumor targeting ability. Furthermore, EcN enhances the tumor targeting effect when combined with chemotherapeutic drugs, providing a promising application of EcN in precise treatment of cancer. EcN provides a great potential in developing novel approach of cancer treatment.